June 12th, 2021

Psychedelic drugs for treatment of mental illness focus of U of C research chair


By The Canadian Press on June 9, 2021.

The campus of the University of Calgary is shown in a Saturday May 29, 2004 file photo. The university has announced a new position that will focus on research into the potential use of psychedelic drugs to improve mental health. THE CANADIAN PRESS/Adrian Wyld

CALGARY – The University of Calgary has announced a new position that will focus on research into the potential use of psychedelic drugs to improve mental health.

It’s believed to be the first of its kind in Canada.

A $3-million commitment for the Parker Psychedelic Research Chair came from Jim Parker, who says he saw his niece make great strides treating her post-traumatic stress disorder at a clinic in California.

He says she received five rounds of intravenous ketamine therapy, precisely dosed under medical supervision.

The field of psychedelic research for mental health is attracting growing interest from the scientific and medical communities.

Ketamine, MDMA (ecstasy) and psilocybin, commonly known as magic mushrooms, have the potential to treat depression, anxiety, post-traumatic stress disorder and addiction.

This report by The Canadian Press was first published June 9, 2021.

Share this story:

7
Subscribe
Notify of
1 Comment
Oldest
Newest Most Voted
Inline Feedbacks
View all comments


1
0
Would love your thoughts, please comment.x
()
x